Cerus Co. (NASDAQ:CERS) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA lessened its position in Cerus Co. (NASDAQ:CERS) by 0.5% during the third quarter, Holdings Channel reports. The fund owned 8,544,000 shares of the biotechnology company’s stock after selling 40,000 shares during the quarter. Primecap Management Co. CA’s holdings in Cerus were worth $14,867,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of CERS. Hood River Capital Management LLC bought a new stake in shares of Cerus during the first quarter valued at approximately $566,000. The Manufacturers Life Insurance Company raised its stake in Cerus by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 7,209 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Cerus by 4.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock worth $365,000 after acquiring an additional 8,982 shares during the period. Creative Planning grew its stake in shares of Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Cerus by 7.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,186,564 shares of the biotechnology company’s stock valued at $2,088,000 after purchasing an additional 78,824 shares during the period. 78.37% of the stock is currently owned by institutional investors.

Insider Activity at Cerus

In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This represents a 4.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus reduced their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, October 17th.

Cerus Stock Up 7.2 %

Shares of CERS stock opened at $1.79 on Friday. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The business’s fifty day moving average is $1.75 and its 200-day moving average is $1.92. The stock has a market cap of $332.42 million, a PE ratio of -16.27 and a beta of 1.20.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.